

**Colo. Rev. Stat. § 12-280-308 Disclosure for MONJUVI® (tafasitamab-cxix)**

**Wholesale Acquisition Cost (WAC) Information for Colorado Prescribers of Prescription Drugs**

MorphoSys US Inc. provides the following information to prescribers in Colorado, in accordance with the requirements in Colo. Rev. Stat. § 12-280-308.

The following amount reflects the Wholesale Acquisition Cost (WAC) of the listed drug, as established in published pricing compendia. The listed WAC price does not necessarily reflect the actual transactional price that a particular patient, provider, or payer will pay for the drug. For instance, it may not take into account discounts or other price concessions on the drug.

**Marketed Product WAC:**

NAME OF PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WAC
MONJUVI® (tafasitamab-cxix) for injection, for intravenous use	73535-208-01	MONJUVI 200 mg single-dose vial	\$1,328.28

**Generic Prescription Drug Products from Same Therapeutic Class:**

None \*\*

\*\* There are no generic prescription drugs from the same “therapeutic class” (as that term is defined in Colo. Rev. Stat. § 12-280-308) listed in the U.S. Food and Drug Administration’s (FDA’s) “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.”

MONJUVI is a registered trademark of MorphoSys AG.  
RC-US-CORP-00045 | August 2020